InsidersTradesSigma
Maravai Lifesciences Holdings, INC. Stock: price and insider trades · United States · SEC (Form 4)
Track the Maravai Lifesciences Holdings, INC. share price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Maravai Lifesciences Holdings, INC. has recorded 149 public disclosures. Market capitalisation: €2.2bn. The latest transaction was disclosed on 1 July 2026 (Retenue fiscale). Among the most active insiders: Herde Kevin. Every trade is openly available.
149
Insider Decl.
0
Thresholds
€1m
3 ops.
Buy Volume
€124m
5 ops.
Sell Volume
33Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 24,492 of 25,973 companies
16.8
score / 100
Value23
Quality10
FCF yld-3.2%
Earn yld-5.9%
EV/EBITDA·
ROE-41%
Gross mgn18%
Net mgn-70%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 1 July 2026
Declarations149 total
65,584 sharesClass A Common StockSEC:0001600301-26-000002:0
351,001 sharesClass A Common StockSEC:0001380632-26-000002:0
46,293 shares0Class A Common StockSEC:0001403373-26-000005:0
46,293 shares0Class A Common StockSEC:0001829753-26-000001:0
46,293 shares0Class A Common StockSEC:0001210525-26-000001:0
46,293 shares0Class A Common StockSEC:0001833453-26-000004:0
5,006 shares@ US$1.790.0016% mcap2.4% of flowClass A Common StockSEC:0001684273-26-000005:0
51,472 shares@ US$3.700.035% mcap50.0% of flowClass A Common StockSEC:0001251299-25-000004:0
Ideal exit: 1 Sept 2026 (T+270)
89,139 shares0Class A Common StockSEC:0001823239-25-000095:0
500,000 sharesClass A Common StockSEC:0001823239-25-000093:0
89,139 shares@ US$2.1644.7% of flowClass A Common StockSEC:0001823239-25-000089:0
89,139 shares@ US$2.1644.7% of flowClass A Common StockSEC:0001823239-25-000088:0
89,139 shares@ US$2.1644.7% of flowClass A Common StockSEC:0001823239-25-000087:0
89,139 shares@ US$2.1631.1% of flowClass A Common StockSEC:0001823239-25-000086:0
89,139 shares@ US$2.1644.7% of flowClass A Common StockSEC:0001823239-25-000085:0
89,139 shares@ US$2.1644.7% of flowClass A Common StockSEC:0001823239-25-000084:0
231,481 shares@ US$2.16100.0% of flowClass A Common StockSEC:0001823239-25-000083:0
89,139 shares@ US$2.1644.7% of flowClass A Common StockSEC:0001823239-25-000082:0
89,139 shares@ US$2.1644.7% of flowClass A Common StockSEC:0001823239-25-000081:0
89,139 shares@ US$2.1635.7% of flowClass A Common StockSEC:0001823239-25-000080:0
2,000,000 sharesClass A Common StockSEC:0000950170-25-084483:0
8,648 shares@ US$2.644.9% of flowClass A Common StockSEC:0001823239-25-000044:0
246,549 sharesClass A Common StockSEC:0001823239-25-000051:0
4,314 shares@ US$2.643.7% of flowClass A Common StockSEC:0001823239-25-000040:0
394,478 sharesClass A Common StockSEC:0001823239-25-000053:0
25 of 149 declarations
About Maravai Lifesciences Holdings, INC.
Maravai LifeSciences Holdings, Inc. (MRVI) is a US life sciences company listed on the NASDAQ, meaning it trades on the American market in the United States. For French-speaking investors evaluating the name, Maravai is best understood as an enabling-tools and reagents platform for biopharma rather than a drug developer. The company provides critical products and services that support the development and manufacture of vaccines, therapeutics and diagnostics, with an operating model built around two core segments: TriLink, historically associated with nucleic acid production, and Cygnus, focused on biologics safety testing. That structure gives Maravai exposure to multiple stages of the life-science value chain, from discovery and research through manufacturing and quality control. The company was founded in 2014 and is headquartered in San Diego, California, a major US biotechnology hub. Over time, Maravai has built a portfolio of technologies and brands around nucleic acid synthesis, mRNA-related materials, and biologics testing solutions. Its customer base includes major biopharmaceutical companies, emerging biotech firms, academic research institutions and diagnostics companies. This diversification is helpful, although demand can still be influenced by biotech funding cycles, vaccine-related volume swings and customer concentration trends in certain product lines. From a competitive standpoint, Maravai occupies a specialized and strategically important niche. In the life sciences ecosystem, companies like MRVI compete on reliability, technical know-how, regulatory compliance, product quality and supply assurance rather than on price alone. Those capabilities matter because customers are often operating in highly regulated environments and need trusted suppliers for mission-critical workflows. Maravai also emphasizes its global commercial reach, serving customers across North America, Europe, the Middle East and Africa, Asia-Pacific, and Latin and Central America. Recent corporate developments have remained important for the investment case. Maravai reported first-quarter 2026 results and highlighted improvement in base revenue excluding high-volume CleanCap revenue tied to commercialized COVID-19 vaccines. The company has also continued to reference domestic manufacturing capacity for mRNA-related products and has seen governance and leadership changes over the past year, which investors will likely view as part of a broader cost and portfolio optimization effort. Overall, MRVI remains a health and pharma infrastructure story: strategically relevant technologies, global customer exposure, and earnings sensitivity to post-pandemic normalization and broader biotech market conditions.
